loading page

How we approach thrombosis risk in children with COVID-19 infection
  • Anjali Sharathkumar,
  • E. Vincent Faustino,
  • Clifford Takemoto
Anjali Sharathkumar
University of Iowa Children's Hospital

Corresponding Author:[email protected]

Author Profile
E. Vincent Faustino
Yale School of Medicine
Author Profile
Clifford Takemoto
St. Jude Children’s Research Hospital
Author Profile

Abstract

Thrombosis within the microvasculature and medium to large vessels is a serious and common complication among critically ill individuals with COVID-19. While children are markedly less likely to develop severe disease than adults, they remain at risk for thrombosis during acute infection and with the post-acute inflammatory illness termed multisystem inflammatory syndrome in children. Significant knowledge deficits in understanding COVID-19 associated coagulopathy and thrombotic risk pose clinical challenges for pediatric providers who must incorporate expert opinion and personal experience to manage individual patients. We discuss clinical scenarios to provide framework for characterizing thrombosis risk and thromboprophylaxis in children with COVID-19.
20 Jan 2021Submission Checks Completed
20 Jan 2021Assigned to Editor
20 Jan 2021Submitted to Pediatric Blood & Cancer
25 Jan 2021Reviewer(s) Assigned
20 Feb 2021Review(s) Completed, Editorial Evaluation Pending
21 Feb 2021Editorial Decision: Revise Minor
04 Mar 2021Submission Checks Completed
04 Mar 2021Assigned to Editor
04 Mar 20211st Revision Received
05 Mar 2021Reviewer(s) Assigned
22 Mar 2021Review(s) Completed, Editorial Evaluation Pending
23 Mar 2021Editorial Decision: Accept